FDA Approves Exelixis’ Cabometyx To Treat Metastatic Differentiated Thyroid Cancer
The U.S. Food and Drug Administration approved Exelixis Inc.’s (EXEL) Cabometyx or cabozantinib for the treatment of adult and pediatric patients 12 years of age and older with locally advanced … Read More